AzTrials
AzTrials

Macular DegenerationNCT07798323

Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.

An observational study of Macular Degeneration, run by Scott Raymond at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this prospective study is to investigate whether ophthalmic artery stenosis (narrowing of the ophthalmic artery) contributes to the development and progression of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD). Read more about this study

Who is it for?
Ages 50 to 80 years
Conditions the study is for
Macular Degeneration
How many people
30 participants
Where
1 siteUnited States
Study dates
1 Sep 2026to Dec 2028
How long will I take part?
1 Year
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: This prospective study will enroll 30 patients from 50-80 years of age with geographic atrophy in one eye and mild to moderate AMD in the fellow eye according to International Classification of Disease (ICD) codes treated at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.

Who may be able to join

  • 50-80 years of age
  • All genders
  • Asymmetric dry AMD with geographic atrophy in at least one eye and reduced disease severity in the other eye according to International Classification of Disease (ICD) codes
  • Treated at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio

Who cannot join

  • Poor image quality that limits quantification
  • GA extending beyond the borders of the SDOCT field of view.
  • Bilateral symmetric geographic atrophy.
  • Diagnosis of wet AMD.
  • Any retinal fluid at baseline.
  • Other concurrent retinal diseases
Show all 9Show fewer
  • Vitreoretinal surgery.
  • Allergy to iodinated contrast agents.
  • Chronic kidney disease with eGFR < 60

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Sara Lautzenhiser Research Coordinator contact

216-444-3026

LAUTZES@ccf.org

United States1 site, 1 recruiting

  • Cleveland Clinic

    Cleveland, Ohio, 44195

    Sara Lautzenhiser Research Coordinator, 216-444-3026, LAUTZES@ccf.org

    Scott Raymond, MD

    Recruiting

Other trials in United States

About this study

The purpose of this prospective study is to investigate whether ophthalmic artery stenosis (narrowing of the ophthalmic artery) contributes to the development and progression of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD).

Medical subject headings
Macular Degeneration

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To demonstrate the ability to quantify ophthalmic artery stenosis using a commercially available, non-invasive imaging modality, PC-CTA.

    Measured: From enrollment to the end of the 12-month study period.

Secondary outcomes (1)

  1. To provide compelling evidence for a connection between ophthalmic artery stenosis and OCT markers of dry AMD disease severity and progression.

    Measured: From enrollment to the end of the 12-month study period.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Sep 2026
  2. Study start1 Sep 2026
  3. Primary completionDec 2028 (estimated)
  4. Study completionDec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (estimated)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT07798323
Sponsor's protocol ID
26-465
Status last verified
Sep 2026
First submitted
27 Aug 2026
Last updated
3 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Witkin AJ, Jaffe GJ, Srivastava SK, Davis JL, Kim JE. Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee. J Vitreoretin Dis. 2023 Dec 21;8(1):9-20. doi: 10.1177/24741264231220224. eCollection 2024 Jan-Feb.

    PubMed 38223782

  • Spaide RF, Vavvas DG. COMPLEMENT INHIBITION FOR GEOGRAPHIC ATROPHY: Review of Salient Functional Outcomes and Perspective. Retina. 2023 Jul 1;43(7):1064-1069. doi: 10.1097/IAE.0000000000003796.

    PubMed 36996460

  • Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Mones J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9.

    PubMed 37865470

  • Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Mones J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8.

    PubMed 37696275

  • van Lookeren Campagne M, LeCouter J, Yaspan BL, Ye W. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol. 2014 Jan;232(2):151-64. doi: 10.1002/path.4266.

    PubMed 24105633

  • Mullins RF, Schoo DP, Sohn EH, Flamme-Wiese MJ, Workamelahu G, Johnston RM, Wang K, Tucker BA, Stone EM. The membrane attack complex in aging human choriocapillaris: relationship to macular degeneration and choroidal thinning. Am J Pathol. 2014 Nov;184(11):3142-53. doi: 10.1016/j.ajpath.2014.07.017. Epub 2014 Sep 7.

    PubMed 25204844

  • Biesemeier A, Taubitz T, Julien S, Yoeruek E, Schraermeyer U. Choriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration. Neurobiol Aging. 2014 Nov;35(11):2562-2573. doi: 10.1016/j.neurobiolaging.2014.05.003. Epub 2014 May 10.

    PubMed 24925811

  • Gelfand BD, Ambati J. A Revised Hemodynamic Theory of Age-Related Macular Degeneration. Trends Mol Med. 2016 Aug;22(8):656-670. doi: 10.1016/j.molmed.2016.06.009. Epub 2016 Jul 13.

    PubMed 27423265

  • Friedman E. A hemodynamic model of the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 1997 Nov;124(5):677-82. doi: 10.1016/s0002-9394(14)70906-7.

    PubMed 9372722

  • Farnsworth PJ, Campeau NG, Diehn FE, Yu L, Leng S, Zhou Z, Fletcher JG, McCollough CH. High-resolution computed tomography angiography of the orbit using a photon-counting computed tomography scanner. Interv Neuroradiol. 2025 Aug;31(4):539-554. doi: 10.1177/15910199231175198. Epub 2023 Jul 3.

    PubMed 37401156

  • Diprose WK, Wang MTM, Reidy J, Ma A, Brodie J, Steinfort B. Ophthalmic artery stenosis on three-dimensional rotational angiography: Interrater agreement, prevalence, and risk factors. Interv Neuroradiol. 2026 Aug;32(4):1267-1271. doi: 10.1177/15910199241233020. Epub 2024 Feb 22.

    PubMed 38387875

  • Nassisi M, Baghdasaryan E, Borrelli E, Ip M, Sadda SR. Choriocapillaris flow impairment surrounding geographic atrophy correlates with disease progression. PLoS One. 2019 Feb 22;14(2):e0212563. doi: 10.1371/journal.pone.0212563. eCollection 2019.

    PubMed 30794627

  • You QS, Camino A, Wang J, Guo Y, Flaxel CJ, Hwang TS, Huang D, Jia Y, Bailey ST. Geographic Atrophy Progression Is Associated With Choriocapillaris Flow Deficits Measured With Optical Coherence Tomographic Angiography. Invest Ophthalmol Vis Sci. 2021 Dec 1;62(15):28. doi: 10.1167/iovs.62.15.28.

    PubMed 34964802

  • Tiosano L, Corradetti G, Sadda SR. Progression of choriocapillaris flow deficits in clinically stable intermediate age-related macular degeneration. Eye (Lond). 2021 Nov;35(11):2991-2998. doi: 10.1038/s41433-020-01298-9. Epub 2021 Jan 7.

    PubMed 33414537

  • Alagorie AR, Verma A, Nassisi M, Sadda SR. Quantitative Assessment of Choriocapillaris Flow Deficits in Eyes with Advanced Age-Related Macular Degeneration Versus Healthy Eyes. Am J Ophthalmol. 2019 Sep;205:132-139. doi: 10.1016/j.ajo.2019.04.037. Epub 2019 May 10.

    PubMed 31078531

Questions about this trial

What is this clinical trial studying?

An observational study of Macular Degeneration, run by Scott Raymond at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sara Lautzenhiser Research Coordinator (216-444-3026, LAUTZES@ccf.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To demonstrate the ability to quantify ophthalmic artery stenosis using a commercially available, non-invasive imaging modality, PC-CTA. (time frame: From enrollment to the end of the 12-month study period.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07798323, which also lists 17 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in